Company profilePharmaceutical#4 of 1,318 in Pakistan3 DRAP alerts

GETZ PHARMA PAKISTAN (PVT) LTD.

Pharmaceutical company · 535 brands · 447 molecules

Ranked #1 of 137 companies in Anti-Infectives

535 registered products 110 pharmaceutical brands 447 distinct molecules 3 DRAP alerts

Company overview

535
registered products
110
pharmaceutical brands
447
distinct molecules
12
therapeutic classes
3
DRAP alerts

GETZ PHARMA PAKISTAN (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 535 product registrations across 447 distinct molecules. It is the 4th largest registrant in Pakistan by product count, and ranks 1st of 137 in Anti-Infectives. Its portfolio is concentrated in Anti-Infectives and Blood Glucose Lowering Drugs, Excluding Insulin. DRAP has issued 3 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by GETZ

824 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Angiotensin-Ii Antagonists, Combinations 3

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

388
ceilings with an approval date
12
not revised in 2+ years
2024
oldest approval year
202412
2025174
2026202
Longest without revision

Top molecules by brand count

Empagliflozin15 brands
Amlodipine13 brands
Artemether13 brands
Ciprofloxacin12 brands
Omeprazole10 brands
Nutritional Supplement / Multivitamin10 brands
Linezolid9 brands
Metformin8 brands
Amoxicillin8 brands

Therapeutic classes

Anti-Infectives · 25Blood Glucose Lowering Drugs, Excluding Insulin · 21Cardiac Care · 17Diabetes · 15Antiinflammatory And Antirheumatic Products · 13Other Beta-Lactam, Cephalosporins & Penems · 13Antidepressants · 13Respiratory Care · 12Drugs For Obstructive Airway Diseases, Inhalants · 12Gastro · 11Antivirals For Systemic Use · 11Angiotensin-Ii Antagonists, Combinations · 11

Conditions treated

General Infections · 16Oral Agents · 11Asthma/Copd · 10Hypertension · 9Ulcer/Reflux/Flatulence/Acidity · 8Bladder & Prostate Disorder · 6High Cholestrol · 5Viral Infection/Hepatitis · 5Insulins · 4Arthritis · 4Anxiety/Depression/Insomnia · 4Pain Killers · 4

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official399 products · Rs 22.08 – Rs 174,457.91
DVAGO343 products · Rs 27.84 – Rs 18,050
Servaid231 products · Rs 35.85 – Rs 9,199.96
Median across source: Rs 389.66

Regulatory record

3 alerts in the DRAP feed we track.

12. Rapid Alert – SPURIOUS CAPSULE GABICA 300 mg (BATCH NO. 518C27)
2026-03-11
17. Volunatry Recall. Osilex-D (Glitz Pharma)
2026-03-11
Rapid Alert: Drug Product; Falsified Risek 40mg Injection identified in the Market
2024-03-27

Competitive set

Companies whose registered portfolio overlaps most with this one.

HILTON PHARMA (PVT) LIMITED142 shared molecules
SEARLE PAKISTAN (PVT.) LTD.136 shared molecules
BIO LABS (PVT) LTD.134 shared molecules
Genix Pharma Private Limited130 shared molecules
NEUTRO PHARMA (PVT) LTD.126 shared molecules
HIGH - Q INTERNATIONAL124 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NABIQASIM INDUSTRIES (PVT) LTD. holds 112 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAgomelatine
HILTON PHARMA (PVT) LIMITED holds 70 molecules not in this portfolio
15 Microgram Of Each Strain H1AlprazolamAlum Hydroxide GelAmodiaquineArtemether/LumafantrineArtichoke
SEARLE PAKISTAN (PVT.) LTD. holds 127 molecules not in this portfolio
AdalimumabAlprazolamAmilorideAminophyllineAmitryptylineAmmonium Chloride

Get the full profile for GETZ

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.